2025
Exploring barriers and potential solutions before implementing a scale-up strategy to expand methadone coverage among people who inject drugs in Tajikistan
O'Hara G, Madden L, Burkhonov A, Alaei A, Mohsinzoda G, Bromberg D, Abdullozoda J, Yusufi S, Altice F. Exploring barriers and potential solutions before implementing a scale-up strategy to expand methadone coverage among people who inject drugs in Tajikistan. Journal Of Substance Use And Addiction Treatment 2025, 172: 209682. PMID: 40139416, DOI: 10.1016/j.josat.2025.209682.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyNominal group techniquePre-implementationImplementation strategiesSecondary HIV prevention strategyHIV prevention strategiesPre-implementation studyAgonist therapyOpioid agonist therapy scale-upHIV epidemicPre-implementation activitiesMethadoneFocus groupsPrevention strategiesCentral Asian regionOpioidGroup techniquePWIDOrganizational factorsNIATxSocietal factorsRecipientsScale-up strategyDrugRetention and dropout from sublingual and extended-release buprenorphine treatment: A comparative analysis of data from a nationally representative sample of commercially-insured people with opiod use disorder in the United States
Ivasiy R, Madden L, Johnson K, Machavariani E, Ahmad B, Oliveros D, Tan J, Kil N, Altice F. Retention and dropout from sublingual and extended-release buprenorphine treatment: A comparative analysis of data from a nationally representative sample of commercially-insured people with opiod use disorder in the United States. International Journal Of Drug Policy 2025, 138: 104748. PMID: 40020306, PMCID: PMC12045481, DOI: 10.1016/j.drugpo.2025.104748.Peer-Reviewed Original ResearchConceptsOpioid use disorderSL-BUPXR-BUPUse disorderRetrospective cohort studyExtended-release buprenorphineReduce treatment discontinuationDays of supplyTreatment discontinuationSublingual buprenorphineReduce overdose riskBuprenorphine treatmentCohort studyHigh dosesPrimary outcomeImpact of dosagePatientsBuprenorphineMonthsMg/dayCommercially-insured individualsProportion of individualsOpioidOverdose riskImprove health outcomesPrescribing methadone in prison predicts linkage to HIV care after release from prison: A randomized and patient preference trial
Mobley A, Wegman M, Bazazi A, Shenoi S, Bromberg D, Ahmad A, Kamarulzaman A, Altice F. Prescribing methadone in prison predicts linkage to HIV care after release from prison: A randomized and patient preference trial. International Journal Of Drug Policy 2025, 137: 104733. PMID: 39923270, PMCID: PMC11875876, DOI: 10.1016/j.drugpo.2025.104733.Peer-Reviewed Original ResearchConceptsLinkage to HIV careHIV careIncrease linkage to HIV careTreatment-as-prevention strategiesHIV treatment cascadeHIV treatment outcomesOpen-label trialCox proportional hazards modelsPatient preference trialOpioid use disorderMalaysia’s largest prison.Impact of methadoneProportional hazards modelTreatment cascadeInverse probability weighted Cox proportional hazards modelAnalytic sampleStudy participantsCareTreatment outcomesPrescribed methadoneOpioidConfounding variablesHIVUse disorderHazards model
2024
Transformation of the HIV treatment cascade for people who inject drugs in Ukraine
Bromberg D, Rhoades D, Madden L, Ivasiy R, Meteliuk A, Pykalo I, Filippovych M, Nikitin B, Farnum S, Fomenko T, Dvoriak S, Altice F. Transformation of the HIV treatment cascade for people who inject drugs in Ukraine. AIDS 2024, 39: 306-311. PMID: 39589135, DOI: 10.1097/qad.0000000000004056.Peer-Reviewed Original ResearchOpioid agonist therapyAntiretroviral therapyImprove HIV treatment outcomesHIV treatment outcomesHIV care cascadeCross-sectional biobehavioral surveyTreatment outcomesCare cascadeUkraine's HIV epidemicPrescription of antiretroviral therapyPrescribed antiretroviral therapyAdherence to antiretroviral therapyHIV treatment cascadeAgonist therapyBiobehavioral surveyOpioid dependenceHIV diagnosisTreatment cascadeHIV epidemicHIVOpioidPWIDTherapyDrugOutcomesTrajectory and progress of opioid agonist therapy programs in the Kyrgyz Republic
Liberman A, Kurmanalieva A, Biibosunova D, Shumskaya N, Ivasiy R, Bromberg D, Madden L, Altice F. Trajectory and progress of opioid agonist therapy programs in the Kyrgyz Republic. Global Health Economics And Sustainability 2024, 2: 2536. PMID: 40212662, PMCID: PMC11985161, DOI: 10.36922/ghes.2536.Peer-Reviewed Original ResearchOpioid agonist therapyHuman immunodeficiency virusMortality of human immunodeficiency virusOpioid agonist therapy programsOpioid use disorderMethadone programsHIV prevention strategiesAgonist therapyImmunodeficiency virusClinical protocolsEffective treatmentUse disorderNeighboring countriesHIV preventionKyrgyz RepublicMethadoneOpioidCentral AsiaIncreased state supportCentral Asian countriesDrugCarceral systemInternational donorsLocal news coveragePolitical challengesThe cascade of care for commercially-insured persons with opioid use disorder and comorbid HIV and HCV infections
Ivasiy R, Madden L, DiDomizio E, Johnson K, Machavariani E, Ahmad B, Oliveros D, Ram A, Kil N, Altice F. The cascade of care for commercially-insured persons with opioid use disorder and comorbid HIV and HCV infections. Drug And Alcohol Dependence 2024, 263: 112410. PMID: 39159600, PMCID: PMC12045330, DOI: 10.1016/j.drugalcdep.2024.112410.Peer-Reviewed Original ResearchOpioid use disorderXR-NTXUse disorderHCV infectionPrescribed MOUDOpioid use disorder cascadePrevalence of opioid use disorderRetrospective cohort studyHigher treatment retentionCascade of careConcurrent infectious diseasesSix-month retentionHCV/HIV coinfectionComorbid HIVCohort studyHospital-based settingPrescribed methadoneHCVMOUD initiationHIVHCV epidemicOpioidMethadoneMOUD prescriptionsTreatment retentionPreferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey.
Bromberg D, Madden L, Fraenkel L, Muthulingam D, Rhoades D, Dvoriak S, Dumchev K, Pykalo I, Altice F. Preferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey. PLOS Global Public Health 2024, 4: e0002725. PMID: 38277422, PMCID: PMC10817130, DOI: 10.1371/journal.pgph.0002725.Peer-Reviewed Original ResearchOpioid agonist therapyWithdrawal symptomsAdverse side effectsAgonist therapySide effectsOpioid use disorderQuality-of-life improvementUse disorderCombined HIVHIV incidenceClinical decision-makingDosing frequencyRespondent-driven samplingOpioidOpioid epidemicAssess preferencesClinical concernPatient preferencesPatientsDelivery strategiesTherapyDisordersHIVPatient concernsWithdrawal
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply